ELAB vs. MRKR, TENX, INAB, SNTI, CDIO, CARA, GOVX, APRE, ATHA, and MTEX
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Marker Therapeutics (MRKR), Tenax Therapeutics (TENX), IN8bio (INAB), Senti Biosciences (SNTI), Cardio Diagnostics (CDIO), Cara Therapeutics (CARA), GeoVax Labs (GOVX), Aprea Therapeutics (APRE), Athira Pharma (ATHA), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry.
Elevai Labs vs.
Elevai Labs (NASDAQ:ELAB) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap multi-sector conglomerates companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
Elevai Labs has higher earnings, but lower revenue than Marker Therapeutics.
In the previous week, Elevai Labs had 3 more articles in the media than Marker Therapeutics. MarketBeat recorded 5 mentions for Elevai Labs and 2 mentions for Marker Therapeutics. Elevai Labs' average media sentiment score of 0.00 beat Marker Therapeutics' score of -0.13 indicating that Elevai Labs is being referred to more favorably in the media.
Marker Therapeutics has a consensus price target of $19.00, suggesting a potential upside of 826.83%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Marker Therapeutics is more favorable than Elevai Labs.
Marker Therapeutics received 72 more outperform votes than Elevai Labs when rated by MarketBeat users.
Marker Therapeutics has a net margin of -179.74% compared to Elevai Labs' net margin of -223.41%. Marker Therapeutics' return on equity of -89.63% beat Elevai Labs' return on equity.
Elevai Labs has a beta of -3.29, indicating that its stock price is 429% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500.
22.2% of Elevai Labs shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 1.3% of Elevai Labs shares are owned by insiders. Comparatively, 17.4% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Marker Therapeutics beats Elevai Labs on 12 of the 15 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
This page (NASDAQ:ELAB) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ELAB Stock Alerts